Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
Obesity · 2025-05 · 33 (5) · 851-860
DOI: 10.1002/oby.24254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 12.03.2025. Verfasst von Beverly G Tchang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, Ne…. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Weight Loss. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage.
Methods
Women participants from SURMOUNT‐1, ‐3, and ‐4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre‐, peri‐, or post‐menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight‐reduction thresholds, and waist to height ratio (WHtR) category shift among those with baseline BMI < 35 kg/m 2 were assessed at end of study treatment.
Results
In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/m 2 reached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT‐3 and ‐4.
Conclusions
In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
- Endocrinology and Nutrition Department, Vall d'Hebron Institut de Recerca (VHIR; Vall d'Hebron Research Institute), Hospital Universitari Vall d'Hebron (Vall d'Hebron University Hospital), Vall d'Hebron Barcelona Campus…
- Eli Lilly and Company, Indianapolis, Indiana, USA.
ORCID-Profile: Beverly G Tchang, Julia P Dunn
Förderung
- Eli Lilly and Company
Zitieren
APA
Tchang, B. G., Mihai, A. C., Stefanski, A., García-Pérez, L. E., Mojdami, D., Jouravskaya, I., Gurbuz, S., Taylor, R., Karanikas, C. A., & Dunn, J. P. (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity, 33(5), 851-860. https://doi.org/10.1002/oby.24254
Vancouver
Tchang BG, Mihai AC, Stefanski A, García-Pérez LE, Mojdami D, Jouravskaya I, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025;33(5):851-860. doi:10.1002/oby.24254
BibTeX
@article{Tchang2025,
author = {Tchang, Beverly G and Mihai, Andreea Ciudin and Stefanski, Adam and García-Pérez, Luis-Emilio and Mojdami, Donna and Jouravskaya, Irina and Gurbuz, Sirel and Taylor, Rebecca and Karanikas, Chrisanthi A and Dunn, Julia P},
title = {Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program},
journal = {Obesity},
year = {2025},
volume = {33},
number = {5},
pages = {851--860},
doi = {10.1002/oby.24254}
}
EUVIMED